Literature DB >> 19015327

Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice.

Mariana Baz1, Yacine Abed, Benjamin Nehmé, Guy Boivin.   

Abstract

The new oral neuraminidase (NA) inhibitor A-322278 was evaluated in mice infected with influenza A/H1N1 wild-type virus or the oseltamivir-resistant (H274Y mutant) virus. A-322278 decreased mortality rates and lung virus titers significantly more than oseltamivir in mice infected with the NA H274Y mutant when therapy was started 4 h before or even 48 h after infection.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19015327      PMCID： PMC2630661          DOI： 10.1128/AAC.01276-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus.

Authors:  Yacine Abed; Nathalie Goyette; Guy Boivin
Journal:  Antivir Ther       Date:  2004-08

2.  Oseltamivir resistance during treatment of influenza A (H5N1) infection.

Authors:  Menno D de Jong; Tan Thanh Tran; Huu Khanh Truong; Minh Hien Vo; Gavin J D Smith; Vinh Chau Nguyen; Van Cam Bach; Tu Qui Phan; Quang Ha Do; Yi Guan; J S Malik Peiris; Tinh Hien Tran; Jeremy Farrar
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus.

Authors:  Rita Medeiros; Marie-Anne Rameix-Welti; Valérie Lorin; Patricia Ribaud; Jean-Claude Manuguerra; Gérard Socie; Catherine Scieux; Nadia Naffakh; Sylvie van der Werf
Journal:  Antivir Ther       Date:  2007

4.  Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.

Authors:  Vasiliy P Mishin; Frederick G Hayden; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child.

Authors:  Mariana Baz; Yacine Abed; Jane McDonald; Guy Boivin
Journal:  Clin Infect Dis       Date:  2006-11-08       Impact factor: 9.079

6.  In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication.

Authors:  Warren M Kati; Debra Montgomery; Robert Carrick; Larisa Gubareva; Clarence Maring; Keith McDaniel; Kevin Steffy; Akhteruzzaman Molla; Frederick Hayden; Dale Kempf; William Kohlbrenner
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

Review 7.  Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.

Authors:  Michael G Ison; Larisa V Gubareva; Robert L Atmar; John Treanor; Frederick G Hayden
Journal:  J Infect Dis       Date:  2006-02-13       Impact factor: 5.226

8.  Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection.

Authors:  Michael G Ison; Vasiliy P Mishin; Thomas J Braciale; Frederick G Hayden; Larisa V Gubareva
Journal:  J Infect Dis       Date:  2006-02-13       Impact factor: 5.226

9.  Enantioselective synthesis of antiinfluenza compound A-315675.

Authors:  David A DeGoey; Hui-Ju Chen; William J Flosi; David J Grampovnik; Clinton M Yeung; Larry L Klein; Dale J Kempf
Journal:  J Org Chem       Date:  2002-08-09       Impact factor: 4.354

Review 10.  Treatment of respiratory virus infections.

Authors:  Yacine Abed; Guy Boivin
Journal:  Antiviral Res       Date:  2006-02-14       Impact factor: 5.970
View more
  4 in total

1.  Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system.

Authors:  James J McSharry; Qingmei Weng; Ashley Brown; Robert Kulawy; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

2.  Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.

Authors:  Donald F Smee; Justin G Julander; E Bart Tarbet; Matthew Gross; Jack Nguyen
Journal:  Antiviral Res       Date:  2012-07-15       Impact factor: 5.970

3.  Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation.

Authors:  Yacine Abed; Philippe Simon; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-04-19       Impact factor: 5.191

Review 4.  The next ten stories on antiviral drug discovery (part E): advents, advances, and adventures.

Authors:  Erik De Clercq
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.